Activation of PTEN by Inhibition of TRPV4 Suppresses Colon Cancer Development

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2019 Jun 14

PMID 31189890

Citations 35

Authors

Xiaoyu Liu

Peng Zhang

Chuanming Xie

Kathy W Y Sham

Simon S M Ng

Yangchao Chen

Christopher H K Cheng

Affiliations

Soon will be listed here.

Abstract

Transient receptor potential vanilloid type 4 (TRPV4) is a Ca-permeable cation channel that is known to be an osmosensor and thermosensor. Currently, limited evidence shows that TRPV4 plays opposite roles in either promoting or inhibiting cancer development in different cancer types. Furthermore, the precise biological functions and the underlying mechanisms of TRPV4 in carcinogenesis are still poorly understood. In this study, we demonstrated that TRPV4 is upregulated in colon cancer and associated with poor prognosis. Contrary to the reported cell death-promoting activity of TRPV4 in certain cancer cells, TRPV4 positively regulates cell survival in human colon cancer in vitro and in vivo. Inhibition of TRPV4 affects the cell cycle progression from the G1 to S phase through modulating the protein expression of D-type cyclins. Apoptosis and autophagy induced by TRPV4 silencing attenuate cell survival and potentiate the anticancer efficacy of chemotherapeutics against colon cancer cells. In addition, PTEN is activated by inhibition of TRPV4 as indicated by the dephosphorylation and increased nuclear localization. Knockdown of PTEN significantly abrogates TRPV4 silencing induced growth inhibition and recovers the capability of clonogenicity, as well as reduced apoptosis in colon cancer cells. Thus, PTEN regulates the antigrowth effects induced by TRPV4 inhibition through both phosphatase-dependent and independent mechanisms. In conclusion, inhibition of TRPV4 suppresses colon cancer development via activation of PTEN pathway. This finding suggests that downregulation of TPRV4 expression or activity would conceivably constitute a novel approach for the treatment of human colon cancer.

Citing Articles

Piezo1 promotes the progression of necrotizing enterocolitis by activating the Ca2(+)/CaMKII-dependent pathway.

Li Z, Jiang Q, Wei J, Dang D, Meng Z, Wu H Commun Biol. 2025; 8(1):417.

PMID: 40074811 PMC: 11904196. DOI: 10.1038/s42003-025-07821-6.

TRPV4 as a Novel Regulator of Ferroptosis in Colon Adenocarcinoma: Implications for Prognosis and Therapeutic Targeting.

Ren X, Chen W, Liu Y, Chen Z, Wang X, Sun X Dig Dis Sci. 2025; .

PMID: 39826064 DOI: 10.1007/s10620-025-08843-0.

The Role of the TRPV4 Channel in Intestinal Physiology and Pathology.

Liu D, Mao M, Liu W, Xie L, Zhong X, Cao W J Inflamm Res. 2024; 17:9307-9317.

PMID: 39588136 PMC: 11587805. DOI: 10.2147/JIR.S483350.

Pharmacological manipulation of TRPC5 by kaempferol attenuates metastasis of gastrointestinal cancer via inhibiting calcium involved in the formation of filopodia.

Yu S, Deng R, Wang W, Zou D, He L, Wei Z Int J Biol Sci. 2024; 20(12):4922-4940.

PMID: 39309444 PMC: 11414399. DOI: 10.7150/ijbs.87829.

A comprehensive analysis of TRP-related gene signature, and immune infiltration in patients with colorectal cancer.

Liu Y, Yao X, Zhao W, Xu J, Zhang H, Huang T Discov Oncol. 2024; 15(1):357.

PMID: 39154317 PMC: 11330954. DOI: 10.1007/s12672-024-01227-2.

References

Adapala R, Thoppil R, Ghosh K, Cappelli H, Dudley A, Paruchuri S . Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene. 2015; 35(3):314-22. PMC: 4948740. DOI: 10.1038/onc.2015.83. View

Gradilone S, Masyuk T, Huang B, Banales J, Lehmann G, Radtke B . Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology. 2010; 139(1):304-14.e2. PMC: 2902576. DOI: 10.1053/j.gastro.2010.04.010. View

Hall D, Cost N, Hegde S, Kellner E, Mikhaylova O, Stratton Y . TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 2014; 26(5):738-53. PMC: 4269832. DOI: 10.1016/j.ccell.2014.09.015. View

Butenko O, Dzamba D, Benesova J, Honsa P, Benfenati V, Rusnakova V . The increased activity of TRPV4 channel in the astrocytes of the adult rat hippocampus after cerebral hypoxia/ischemia. PLoS One. 2012; 7(6):e39959. PMC: 3384594. DOI: 10.1371/journal.pone.0039959. View

Roderick H, Cook S . Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008; 8(5):361-75. DOI: 10.1038/nrc2374. View

Fusi C, Materazzi S, Minocci D, Maio V, Oranges T, Massi D . Transient receptor potential vanilloid 4 (TRPV4) is downregulated in keratinocytes in human non-melanoma skin cancer. J Invest Dermatol. 2014; 134(9):2408-2417. DOI: 10.1038/jid.2014.145. View

Everaerts W, Zhen X, Ghosh D, Vriens J, Gevaert T, Gilbert J . Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010; 107(44):19084-9. PMC: 2973867. DOI: 10.1073/pnas.1005333107. View

Ma X, Blenis J . Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009; 10(5):307-18. DOI: 10.1038/nrm2672. View

Fiorio Pla A, Ong H, Cheng K, Brossa A, Bussolati B, Lockwich T . TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling. Oncogene. 2011; 31(2):200-12. PMC: 5934994. DOI: 10.1038/onc.2011.231. View

10.

Fingar D, Richardson C, Tee A, Cheatham L, Tsou C, Blenis J . mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2003; 24(1):200-16. PMC: 303352. DOI: 10.1128/MCB.24.1.200-216.2004. View

11.

Yang S, Cao Q, Zhou K, Feng Y, Wang Y . Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene. 2009; 28(10):1320-8. DOI: 10.1038/onc.2008.475. View

12.

White J, Cibelli M, Urban L, Nilius B, McGeown J, Nagy I . TRPV4: Molecular Conductor of a Diverse Orchestra. Physiol Rev. 2016; 96(3):911-73. DOI: 10.1152/physrev.00016.2015. View

13.

Wang Q, Guo W, Hao B, Shi X, Lu Y, Wong C . Mechanistic study of TRPM2-Ca(2+)-CAMK2-BECN1 signaling in oxidative stress-induced autophagy inhibition. Autophagy. 2016; 12(8):1340-54. PMC: 4968236. DOI: 10.1080/15548627.2016.1187365. View

14.

Monteith G, Prevarskaya N, Roberts-Thomson S . The calcium-cancer signalling nexus. Nat Rev Cancer. 2017; 17(6):367-380. DOI: 10.1038/nrc.2017.18. View

15.

Thorneloe K, Sulpizio A, Lin Z, Figueroa D, Clouse A, McCafferty G . N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces.... J Pharmacol Exp Ther. 2008; 326(2):432-42. DOI: 10.1124/jpet.108.139295. View

16.

Thoppil R, Adapala R, Cappelli H, Kondeti V, Dudley A, Meszaros J . TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation. Sci Rep. 2015; 5:14257. PMC: 4585691. DOI: 10.1038/srep14257. View

17.

Shi Y, Ding X, He Z, Zhou K, Wang Q, Wang Y . Critical role of TRPC6 channels in G2 phase transition and the development of human oesophageal cancer. Gut. 2009; 58(11):1443-50. DOI: 10.1136/gut.2009.181735. View

18.

Baldin V, Lukas J, Marcote M, Pagano M, Draetta G . Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993; 7(5):812-21. DOI: 10.1101/gad.7.5.812. View

19.

Moran M, McAlexander M, Biro T, Szallasi A . Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011; 10(8):601-20. DOI: 10.1038/nrd3456. View

20.

Zhang P, Liu X, Li H, Chen Z, Yao X, Jin J . TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPKα/mTOR pathway. Sci Rep. 2017; 7(1):3158. PMC: 5466655. DOI: 10.1038/s41598-017-03230-w. View